Establishing an in vitro screening system for synthetic signal peptides in Chinese hamster ovary (CHO) cells is crucial, as selecting an appropriate signal peptide ensures efficient secretion and enhances therapeutic protein production. However, expanding library sizes to increase peptide diversity and improving screening efficiency by minimizing false positives remain significant challenges. In this study, we optimized a synthetic-biology-driven in vitro screening system by incorporating the Beacon optofluidic system to minimize false positives and generating stable CHO cell pools in serum-free suspension culture to accommodate larger libraries. This platform enabled the high-throughput screening of diverse signal peptide variants at the single-cell level, exceeding the limits of conventional fluorescence-activated cell sorting (FACS)-based methods. Using this system, we successfully identified novel synthetic signal peptides for the heavy chain (HC) and light chain (LC) that enhanced the specific protein productivity (qp) of the monoclonal antibody (mAb). The selected synthetic signal peptide combinations improved qp in both transient and stable gene expression systems, with the best-performing combination increasing qp by up to 2.23-fold compared with the native signal peptide. Additionally, substituting the native signal peptide with a screened synthetic signal peptide did not significantly affect the N-terminal cleavage, N-linked glycosylation, size heterogeneity, and biological activity of the mAb. Overall, the synthetic-biology-based in vitro screening system developed in this study enabled the discovery of novel synthetic signal peptides that significantly improved mAb productivity in CHO cells without compromising product quality and function.
No takes yet. Share an insight, caveat, or question.
Heo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: